MiNK Therapeutics (INKT) Competitors $14.47 -0.23 (-1.56%) Closing price 04:00 PM EasternExtended Trading$14.62 +0.15 (+1.07%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. ANNX, IMMP, SCPH, ALMS, TKNO, SGMT, ALLO, ALEC, FENC, and SOPHShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Annexon (ANNX), Prima BioMed (IMMP), scPharmaceuticals (SCPH), Alumis (ALMS), Alpha Teknova (TKNO), Sagimet Biosciences (SGMT), Allogene Therapeutics (ALLO), Alector (ALEC), Adherex Technologies (FENC), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Its Competitors Annexon Prima BioMed scPharmaceuticals Alumis Alpha Teknova Sagimet Biosciences Allogene Therapeutics Alector Adherex Technologies SOPHiA GENETICS Annexon (NASDAQ:ANNX) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings. Does the media refer more to ANNX or INKT? In the previous week, MiNK Therapeutics had 1 more articles in the media than Annexon. MarketBeat recorded 12 mentions for MiNK Therapeutics and 11 mentions for Annexon. Annexon's average media sentiment score of 0.65 beat MiNK Therapeutics' score of 0.02 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 0 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiNK Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has better valuation and earnings, ANNX or INKT? MiNK Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnexonN/AN/A-$138.20M-$1.29-1.66MiNK TherapeuticsN/AN/A-$9.51M-$2.88-5.02 Do analysts recommend ANNX or INKT? Annexon currently has a consensus price target of $12.50, suggesting a potential upside of 484.11%. MiNK Therapeutics has a consensus price target of $37.50, suggesting a potential upside of 159.16%. Given Annexon's stronger consensus rating and higher probable upside, equities research analysts clearly believe Annexon is more favorable than MiNK Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Which has more risk & volatility, ANNX or INKT? Annexon has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Do institutionals & insiders hold more shares of ANNX or INKT? 2.9% of MiNK Therapeutics shares are held by institutional investors. 12.7% of Annexon shares are held by company insiders. Comparatively, 22.5% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is ANNX or INKT more profitable? MiNK Therapeutics' return on equity of 0.00% beat Annexon's return on equity.Company Net Margins Return on Equity Return on Assets AnnexonN/A -70.04% -57.67% MiNK Therapeutics N/A N/A -227.24% SummaryAnnexon beats MiNK Therapeutics on 8 of the 14 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.68M$3.09B$5.74B$9.59BDividend YieldN/A2.22%4.54%4.09%P/E Ratio-5.0220.5430.3625.02Price / SalesN/A282.27402.37170.96Price / CashN/A42.8237.3459.16Price / Book-2.297.788.956.28Net Income-$9.51M-$54.72M$3.26B$265.47M7 Day Performance-17.31%-0.72%-0.19%-2.02%1 Month Performance-28.75%4.44%3.83%0.34%1 Year Performance72.47%9.17%28.77%20.73% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.9333 of 5 stars$14.47-1.6%$37.50+159.2%+75.2%$57.68MN/A-5.0230Earnings ReportAnalyst DowngradeANNXAnnexon2.8987 of 5 stars$2.43+2.2%$12.50+414.0%-63.4%$261.66MN/A-2.0260Earnings ReportAnalyst UpgradeGap UpIMMPPrima BioMed1.1217 of 5 stars$1.73+0.6%$7.00+304.6%-23.7%$253.95M$5.14M0.002,021Gap DownSCPHscPharmaceuticals4.5585 of 5 stars$4.73-4.5%$14.00+196.3%-12.8%$251.52M$36.33M-2.6130Short Interest ↓ALMSAlumis2.9872 of 5 stars$4.67+6.3%$20.17+332.3%-63.6%$249.58MN/A0.00N/ANews CoverageEarnings ReportAnalyst RevisionGap DownTKNOAlpha Teknova1.8785 of 5 stars$4.66-3.0%$10.00+114.7%-9.4%$248.82M$37.74M-11.07240SGMTSagimet Biosciences3.3514 of 5 stars$7.97-8.1%$25.67+222.0%+145.0%$242.75M$2M-4.338Positive NewsEarnings ReportALLOAllogene Therapeutics3.0101 of 5 stars$1.12+4.2%$8.44+657.3%-60.4%$241.70M$20K-1.00310Earnings ReportAnalyst RevisionALECAlector3.6086 of 5 stars$2.36-4.3%$4.17+76.9%-58.8%$238.35M$100.56M-2.03270FENCAdherex Technologies1.8488 of 5 stars$8.55+0.2%$13.00+52.0%+38.3%$237.36M$47.54M-16.7410News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionSOPHSOPHiA GENETICS3.007 of 5 stars$3.47+5.8%$8.00+130.5%+0.3%$235.18M$65.17M-7.91520Short Interest ↓ Related Companies and Tools Related Companies Annexon Competitors Prima BioMed Competitors scPharmaceuticals Competitors Alumis Competitors Alpha Teknova Competitors Sagimet Biosciences Competitors Allogene Therapeutics Competitors Alector Competitors Adherex Technologies Competitors SOPHiA GENETICS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access